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1. Introduction 
Dantrolene sodium (l- { [5-@-nitrophenyl)furfuryl- 
idene]amino}hydantoin sodium was synthesized in 
1967 [I] and later shown to act as a depressant of 
muscle contractility. It has proven to be effective in 
the treatment of various forms of spasticity [2] as 
well as in the prophylaxis and treatment of the 
potentially lethal malignant hyperthermia muscle 
disorder in swine [3] and in human patients [4]. 
The drug appears to act preferentially on skeletal 
muscle [.5] but has also effect in smooth muscle [6]. 
In particular, it has no effect on neuromuscular 
transmission [7] nor on the cardiovascular system 
[8]. Various suggestions have been made as to the 
possible of action of dantrolene sodium, but one 
hypothesis that has gained momentum in recent 
years is that of an inhibition of the release of calcium 
from muscle intracellular stores, particularly the 
sarcoplasmic reticulum. On the basis of pharmaco- 
logical evidence, the existence of an intracellular 
compartment able to bind dantrolene sodium with 
high affinity was postulated [9]. 
In this work, the binding of [ 14C]dantrolene 
sodium to intracellular membranous systems from 
heart and skeletal muscle has been studied. It will be 
shown that heart and skeletal muscle sarcoplasmic 
reticulum and skeletal muscle mitochondria bind the 
drug with low affinity. Skeletal muscle sarcoplasmic 
reticulum however possesses a separate class of sites 
which binds dantrolene sodium with high affinity. 
2. Methods 
Sarcoplasmic reticulum was preprared from the 
skeletal muscle (m. gracilis) and the heart muscle 
Elsevier/North-Holland Biomedical Press 
from pigs according to [lo]. Mitochondria were 
prepared from pig skeletal muscle (m. grucilis) accord- 
ing to [ 111. The protein concentration in the suspen- 
sion was determined with the biuret procedure [ 121. 
The binding of [ 14C] dantrolene sodium (Norwich- 
Eaton Pharmaceuticals) was measured with the equi- 
librium dialysis system [ 131, using a high-permeability 
membrane (cut off mol. wt 10 000) and 1 ml cells. 
The standard medium contained 50 mM KCl, 0.5 mM 
CaC12, 0.5 mM EGTA, 5 mM K,-ATP, 10 mM Hepes 
(pH 7.0), 1 mg sarcoplasmic reticulum or mitochon- 
drial protein and various amount of labelled dan- 
trolene sodium dissolved in DMSO. The cells were 
rotated at 12 rev./min for 60 min at 37’C. Aliquots 
of the suspension were counted in a Philips scintilla- 
tion counter using Instagel as the scintillation fluid. 
3. Results and discussion 
Fig.1 shows a Scatchard plot of dantrolene sodium 
binding to skeletal muscle sarcoplasmic reticulum. 
The plot clearly demonstrates the existence of 
2 classes of binding sites, differing widely in their 
affinity for the drug. Most likely the low affinity 
leg of the plot of fig.1 and also of the plots of fig.2 
and 3 reflect the saturation of the phospholipids 
of the membranes with dantrolene sodium. Fig.2 
and 3 show analogous Scatchard plots of the bind- 
ing of dantrolene sodium to heart sarcoplasmic 
reticulum, and to skeletal muscle mitochondria. 
In both cases it is evident that the high affinity 
class of binding sites is absent. The high affinity 
of skeletal muscle sarcoplasmic reticulum for dan- 
trolene sodium (Kd = 5 nM, fig.1) suggests a specific 
site of action for this drug. The functional rele- 
vance of the low affinity class of binding sites iden- 
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Fig.1. A Scatchard plot of dantrolene sodium binding to 
skeletal muscle sarcoplasmic reticulum, showing a highaffin- 
ity class of binding sites (K - 5 nM, capacity 6 pmol/mg 
protein) and a low affinity class of binding sites (Kd = 10 PM, 
capacity 3.3 nmoljmg prot Z:. 
tidied in the three membrane systems is less evident. 
The data further indicate a molecular difference 
between heart and skeletal muscle sarcoplasmic 
reticulum, and offer a very promising tool for investi- 
gating this difference. We are now working on the 
identification of the component which specifically 
binds dantrolene sodium in skeletal muscle sarco- 
plasmic reticulum. Preliminary evidence obtained in 
liposomes containing reconstituted purified Ca*+- 
Mg*‘-ATPase indicate that the dantrolene sodium 
receptor may be the ATPase. 
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\ Scatchard plot of dantrolene sodium binding to 
heart sarcoplasmic reticulum showing a low affinity class of 
binding sites (Kd = 2 PM, capacity 1.2 nmol/mg protein). 
Fig.3. A Scatchard plot of dantrolene sodium binding to 
skeletal muscle mitochondria, showing a low affinity class of 
binding sites (Kd = 2.5 MM, capacity 0.8 nmol/mg protein). 
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